In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Jiangsu Hengrui Medicine Co., Ltd.

https://www.hrs.com.cn/index.html

Latest From Jiangsu Hengrui Medicine Co., Ltd.

New China Indications For Merck, Novo, Boehringer Drugs

China continues with a post-coronavirus approvals rush, granting additional indications to Merck's Keytruda, BI's Ofev and Novo Nordisk's Norditropin.

China Approvals

New China Approvals Include Amgen, Sanofi, Hengrui Drugs, Innovent Biosimilar

Several high-profile products including Dupixent gain approvals in China.

China Approvals

Volume-Based Purchasing Looms Larger In Post-Coronavirus China

China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.

Commercial Pricing Strategies

Hengrui Quickly Fills Celgene Void Amid Nationalism Surge In China

China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.

China Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register